| Bronchiolitis. Origins and optimal management. | |
| | |
MedLine Citation:
|
PMID: 7641603 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
There is currently no prospect of an end to the annual epidemics of acute bronchiolitis, which cause considerable morbidity in previously healthy infants and are a major threat to the well-being of infants with underlying cardiac, respiratory or immunological disease. The respiratory syncytial virus remains the major cause of this condition, and prospects of developing a vaccine remain bleak while our understanding of the viral-host interaction remain incomplete. Treatment of patients with this condition has remained essentially unchanged for more than 30 years. Correction of hypoxia with oxygen, minimal handling to reduce the risk of exhaustion and careful noninvasive monitoring for complications such as apnoea and respiratory failure are the mainstays of management. Mortality in at-risk groups has fallen substantially during the past 10 years. This appears to be due to improved supportive and intensive care. The role of the antiviral agent ribavirin in the improved outcome, if any, is unclear. Other novel therapies have been tried, but none have been shown to significantly alter the natural history of the condition. The only effective preventive intervention currently available is strict adherence to measures designed to prevent nosocomial infection. This condition is likely to remain a continuing challenge to paediatricians for the foreseeable future. |
| | |
Authors:
|
M L Everard |
Related Documents
:
|
7825453 - New interpretation and management of dry lung syndrome: a case report. 23560803 - Infant feeding practices in the first 24 to 48 hours of life in healthy term infants. 739343 - Retinopathy of prematurity in the intensive care nursery. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Drugs Volume: 49 ISSN: 0012-6667 ISO Abbreviation: Drugs Publication Date: 1995 Jun |
Date Detail:
|
Created Date: 1995-09-20 Completed Date: 1995-09-20 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 7600076 Medline TA: Drugs Country: NEW ZEALAND |
Other Details:
|
Languages: eng Pagination: 885-96 Citation Subset: IM |
Affiliation:
|
Sheffield Children's Hospital, England. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anti-Bacterial Agents
/
therapeutic use Bronchiolitis / diagnosis*, prevention & control, therapy* Combined Modality Therapy Diagnosis, Differential Humans Immunoglobulins / administration & dosage Infant Oxygen / therapeutic use Ribavirin / therapeutic use Vaccines / administration & dosage |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Bacterial Agents; 0/Immunoglobulins; 0/Vaccines; 36791-04-5/Ribavirin; 7782-44-7/Oxygen |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Novel antithrombotic drugs in development.
Next Document: Drug treatment associated with heart valve replacement.